Abstract Improved knowledge of retinoblastoma chemotherapy resistance is needed to raise treatment efficiency. The objective of this study was to test whether etoposide alters glucosyl-ceramide, ceramide, sphingosine, and sphingosine-1-phosphate (sphingosine-1-P) levels in parental retinoblastoma cells (WERI Rb1) or their etoposide-resistant subclones (WERI EtoR). WERI Rb1 and WERI EtoR were incubated with 400 ng/ml etoposide for 24 h. Levels of glucosyl-ceramides, ceramides, sphingosine, sphingosine-1-P were detected by Q-TOF mass spectrometry. Statistical analysis was done by ANOVA followed by Tukey post-hoc test (p < 0.05). The mRNA expression of sphingolipid pathways enzymes in WERI Rb1, WERI EtoR and four human retinoblastoma tissue samples was analyzed by quantitative real-time PCR. Pathways enzymes mRNA expression confirmed similarities of human sphingolipid metabolism in both cell lines and tissue samples, but different relative expression. Significant up-regulation of sphingosine was seen in both cell lines (p < 0.001). Only sphingosine-1-P up-regulation was significantly increased in WERI EtoR (p < 0.01), but not in WERI Rb1 (p > 0.2). Both cell lines upregulate proapoptotic sphingosine after etoposide incubation, but only WERI EtoR produces additional survival favorable sphingosine-1-P. These data may suggest a role of sphingosine-1-P in retinoblastoma chemotherapy resistance, although this seems not to be the only resistance mechanism.
Introduction
Retinoblastoma is the most common malignant eye tumor of the childhood with a lethality rates that reaches up to 95% if left untreated [1, 2] . Currently, the most effective treatment in retinoblastoma is the surgical removal/ enucleation of the affected eye, with obvious disadvantages for the child [2] . In bilateral involvement, chemotherapy is administered in order to facilitate partial tumor regression and size reduction, but chemotherapy resistance frequently leads all too often to limited efficiency [3] [4] [5] [6] [7] [8] [9] [10] . Therefore, new adjuvant therapy is needed to raise therapy efficiency in chemotherapy resistant retinoblastoma.
Recent advances in research have elucidated a central role of sphingolipids in cellular apoptosis and survival signaling mechanisms [11] . Of particular interest is the apoptotic effect of glucosyl-ceramide, ceramide, and sphingosine up-regulation, whereas sphingosine-1-phosphate (sphingosine-1-P) upregulation induces cell survival [11] (see Fig. 1 ). The apoptotic effect of sphingolipids has been demonstrated in various tumors including stomach, lung and kidney cancer, nonHodgkin-lymphoma, colon adenomacarcinoma, astrocytoma, glioblastoma, and breast cancer [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] . Furthermore, glucosyl-ceramide, ceramide and sphingosine upregulation has been associated with increased chemotherapy efficiency in in vitro and in vivo tumor models [22] [23] [24] . In contrast, sphingosine-1-P down-regulation has been accompanied with increased chemotherapy efficiency in tumor cells [25] [26] [27] [28] .
Therefore, we hypothesized, that chemotherapy treatment in resistant retinoblastoma cells induces sphingosine-1-P expression, thus reducing chemotherapy efficiency. The objective of this study was to test, whether etoposide alters the level of glucosyl-ceramide, ceramide, sphingosine, and sphingosine-1-P in parental retinoblastoma cells (WERI Rb1) or their etoposide-resistant subclone (WERI EtoR).
Methods Authentication Verifications of WERI Rb Cell Lines
DNA fingerprinting of both human WERI Rb cell lines was confirmed by carried out DNA profiling using 8 different and highly polymorphic short tandem repeat (STR) loci. Authentication verifications were done by Leibniz Institute DSMZ -German Collection of Microorganisms and Cell Cultures (www.dsmz.de). Generated STR profiles of used cell lines showed a full match of the respective parental reference STR profiles as indicated by a search of the database of cell banks ATCC (USA), JCRB (Japan), RIKEN (Japan), KCLB (Korea), and DSMZ. Samples of WERI Rb1 and WERI EtoR were taken from authenticated cell cultures.
Also, both WERI Rb cell lines were tested for presence of mitochondrial DNA sequences from rodent cells as mouse, rat, Chinese and Syrian hamster. Results revealed no detection of any mitochondrial sequences from mouse, rat or Chinese hamster, and Syrian hamster cells in the human samples at a detection limit of 1:10 5 . The samples are derived of pure human cell cultures.
WERI Rb1 and WERI Rb1 Etoposide-Resistant Subclones (WERI EtoR)
The retinoblastoma cell line WERI Rb1 and the etoposideresistant WERI Rb1 (WERI EtoR) subclone were a courtesy of Dr. H. Stephan (University Hospital, Essen, Germany) [29] . Both cell lines were cultivated in cell culture medium containing DMEM supplemented with 15% FBS, 4 mM L-glutamine, 50 mM ß-mercaptoethanol, 10 mg insulin/mL, and penicillin/ streptomycin at 37°C at 10% CO 2 and 80% humidity [30] . DAPI/propidium iodide assays to determine apoptosis/ necrosis rate confirmed chemotherapy sensitivity of WERI Rb1, but resistance of WERI EtoR after 400 ng/ml etoposide incubation for 24 h (Fig. 2) .
Glucosyl-Ceramide, Ceramide, Sphingosine and Sphingosin-1-P Quantification WERI Rb1 and WERI EtoR were incubated with DMEM supplemented with 400 ng/ml etoposide or vehicle control for 24 h. Ceramides, sphingosine, and S1P were extracted and quantified as recently described [31] [32] [33] . Briefly, lipid extraction of cells was performed using C17-sphingosine, C17-S1P, and C17-ceramide as internal standards. Sample analysis was carried out by rapid resolution LC-MS/MS using a QTOF 6530 mass spectrometer (Agilent Technologies, Waldbronn, Germany) operating in the positive ESI mode. The precursor ions of sphingosine (m/z 300.289,) C17-sphingosine (m/z 286.274), S1P (m/z 380.256), C17-S1P (m/z 366.240), C16-ceramide (m/z 520.508), and C17- 
Quantitative PCR (RT-PCR) for Sphingolipid Enzyme mRNA in Retinoblastoma Samples and Cell Lines
To confirm the expression of sphingolipid enzyme mRNA, we used tumor tissue from four anonymous diagnosed retinoblastoma patients after enucleation. Biodata have been summarized in Table 1 . Ethic committee approval of Charité Universitätsmedizin (Berlin, Germany) was obtained and the study was conducted following the guidelines of the Helsinki declaration. To obtain mRNA, 5 × 10 6 -1 × 10 7 sensitive WERI Rb1 (n = 5) and resistant WERI EtoR cells (n = 5) were snap frozen in liquid nitrogen and stored at −80°C until RNA isolation. Total RNA was extracted from four different retinoblastoma tumor tissues. The Gene Elute Mammalian Total RNA Miniprep Kit (Sigma-Aldrich, Munich, Germany) was used for total RNA extraction following manufacturer's instructions. Purity and concentration of RNA was quantified in a BioSpectrometer (Eppendorf, Hamburg, Germany). For cDNA synthesis, 1 μg total RNA was reverse-transcribed to cDNA using the First Strand cDNA Synthesis Kit (Thermo Fisher Scientific, Darmstadt, Germany).
The gene expression levels in the samples were determined by reverse-transcription quantitative real-time PCR (RTqPCR) using PowerUp™ SYBR Green chemistry (Thermo Fisher Scientific, UK). PCR primers for the genes of interest were designed using Primer-BLAST [34] . Where possible, the primers spanned exons and all of PCR products were within the 136-150 bp size range. Primer sequences are listed in Table 2 . Beta-2-microglobulin (B2M; NM_004048.2) was chosen as the reference gene for normalization purposes. 2.5 ng of cDNA was used per 10 μl RT-qPCR with 500 nM of the sense and antisense primers and run on a StepOnePlus real-time PCR system (Applied Biosystems, UK). PCRs were carried out in triplicate per primer set per sample. The resultant cycle threshold values (C T ) were used to obtain the delta C T (ΔC T = C T target gene -C T B2M reference gene) for each sample. The normalized expression levels of the genes of interest were calculated as 2^(
−ΔCT)
. 
Statistical Analysis
Data are presented as mean ± SEM ± SD unless otherwise stated. Statistical Analysis was done by ANOVA followed by a Tukey post-hoc test using Statistical Software (V10.0, Statsoft, Tulsa, Ok, USA). P-values below 0.05 were considered statistically significant.
Results

Retinoblastoma Tissue Biodata
Four human retinoblastoma patients' samples were included in this study. One patient had no treatment before enucleation, one had chemotherapy before, one had beam radiation before and one had combined chemotherapy/beam radiation before. Three patients experienced bilateral retinoblastoma and one patient only unilateral retinoblastoma. None of the four patients have been diagnosed with metastasis or had risk factors for metastasis. All data have been displayed in Table 1 . SGMS1_REV  TGGTGTGCCTGAATCATGCTG  SGMS2_FOR  CTCTACCTGTGCCTGGAATGC  SGMS2_REV  CGCTGAAGAGGAAGTCTCCAC  SMPD1_FOR  TGGCTGCTCAGTTCTTTGGC   SMPD1_REV  TGGTACACACGGTAACCAGGA  SMPD2_FOR  TTTGCTGGAGGAGGTGTGGAG  SMPD2_REV  AAGCTCCTGGATTGGATGTTTGG  SMPD3_FOR  GTGTAACGACGATGCCCTGG  SMPD3_REV  GGATGGCGCTGTCCTCTTG   SMPD4_FOR  GGGGCGGTACCAGATCATCA  SMPD4_REV  TGTGGTTGATGGCAGACGAC  ENPP7_FOR  TGCTGCACACAGAATCTGCTC  ENPP7_REV  GGCGTTATGCGACCTCAGAC  ASAH1_FOR  CTGTCCTCAACAAGCTGACCG   ASAH1_REV  TGTCTCAGAGGCCGCATTCT  ASAH2_FOR  GGGCCATTTGTAGCAGCCTT   ASAH2_REV  AATGCACATGCTAGGCCCAC  ACER1_FOR  GTGGACTGGTGTGAGAGCAAC  ACER1_REV  ACGTAAATGTAGCGGGAGCG   ACER2_FOR  GTGTCCTGTCTGCGGTTACG   ACER2_REV  AGGCCCAGCTTAAACACACG  ACER3_FOR  CCGAGTTCTGGAATACAGTGAGTAA   ACER3_REV  GAAGCACCAGGATCCCATTCC  CERK_FOR  CTGCACGGTCTGATTGGGAG   CERK_REV  CCACGGTGGAGTAACACACG   CERKL_FOR  TCGATGGATGTCCCCTAACCA  CERKL_REV  TCCCTGTGCCCTCCTTTCTT   SPHK1_FOR  TGGCTGAGGCTGAAATCTCCT  SPHK1_REV  CGTTCACCACCTCGTGCAT   SPHK2_FOR  TTCCGGAAGAAAGGGATCTGGG   SPHK2_REV  GACCTTCAGCTCTCCAACACTG  S1P1_FOR TGAGCGAGGCTGCGGTT Sequence name Sequence (5'-3') S1P1_REV CGCTACTCCAGACGAACGCTA S1P2_FOR GCCTAGCCAGTTCTGAAAGCC S1P2_REV GAGGTCGTCTCCTGCGTTTC S1P3_FOR GACGGAGGAGCCCTTTTTCAAC S1P3_REV GGCATTCACAGACGATTAGCTCC S1P4_FOR CGCGACGCTGGGTCTACTAT S1P4_REV CCCTCCCGTAGGAACCACTG S1P5_FOR CTCACTCGGTTCAAGGCAGC S1P5_REV GGAGCTTGCCGGTGTAGTTG B2M_FOR CTACACTGAATTCACCCCCACTG B2M_REV AATGCGGCATCTTCAAACCTCC PCR primer sequences used for quantitative PCR of sphingolipid gene expression: sphingosine kinase 1 (SPHK1), sphingosine kinase 2 (SPHK2), sphingosphingosine-1-phosphate receptor 1 (S1P1), sphingosphingosine-1-phosphat receptor 2 (S1P2), sphingosphingosine-1-phosphate receptor 3 (S1P3), sphingosphingosine-1-phosphate receptor 4 (S1P4), sphingosphingosine-1-phosphate receptor 5 (S1P5), sphingosphingosine-1-phosphate phosphatase 1 (SGPP1), sphingosphingosine-1-phosphate phosphatase 2 (SGPP2), Ceramide synthase 1 (LASS1), ceramide synthase 2 (LASS2), ceramide synthase 3 (LASS3), ceramide synthase 4 (LASS4), ceramide synthase 5 (LASS5), ceramide synthase 6 (LASS6), acid ceramidase 1 (ASAH1), acid ceramidase 2 (ASAH2), alkaline ceramidase 1 (ACER1), alkaline ceramidase 2 (ACER2), alkaline ceramidase 3 (ACER3), ceramide kinase (CERK), ceramide kinase like (CERKL), sphingomyelin synthase 1 (SGMS1), sphingomyelin synthase 2 (SGMS2), acid sphingomyelinase 1 (SMPD1), neutral sphingomyelinase 2 (SMPD2), neutral sphingomyelinase 3 (SMPD3), neutral sphingomyelinase 4 (SMPD4), alkaline sphingomyelinase (ENPP7), beta-2-microglobulin (B2M)
Etoposide-Induced Upregulation of Apoptotic Sphingosine in WERI Rb1 and WERI EtoR WERI Rb1 vehicle control, WERI Rb1 400 ng/ml etoposide, WERI EtoR vehicle, and WERI EtoR 400 ng/ml etoposide were incubated with DMEM supplemented with etoposide or vehicle control and harvested after 24 h. Levels for apoptotic glucosyl-ceramide, ceramide and sphingosine were evaluated by mass spectroscopy for all treatment groups. Statistical significant upregulation of apoptotic sphingosine was seen after etoposide treatment in WERI Rb1 and WERI EtoR (p < 0.01, Fig. 3a , Table 3 ). Slight downregulation of ceramide and glu-ceramide were seen after etoposide treatment in WERI Rb1 and WERI EtoR, but this was only statistical significant for ceramide in WERI Rb1 after etoposide treatment (p < 0.5; Fig. 3b and d, Table 3 ).
Etoposide-Induced Upregulation of Survival Favoring Sphingosine-1-P Only in Etoposide Resistant WERI EtoR WERI Rb1 vehicle control, WERI Rb1 400 ng/ml etoposide, WERI EtoR vehicle, and WERI EtoR 400 ng/ ml etoposide were incubated with DMEM supplemented with etoposide or vehicle control for 24 h and were harvested. Levels for survival favoring sphingosine-1-P were evaluated by mass spectroscopy. Statistical significant upregulation of sphingosine-1-P was seen after etoposide Fig. 3c , Table 3 ).
Quantitative Sphingolipid mRNA Expression in Human Retinoblastoma Samples and in WERI Rb1 and WERI EtoR
Gene expression alterations in sphingolipid metabolism was measured by quantitative PCR in four human retinoblastoma samples and in WERI Rb1 and WERI EtoR. Figure 4 displays the relative expression of sphingosine kinase 1 (SPHK1), sphingosine kinase 2 (SPHK2), sphingosphingosine-1-phosphate receptor 1 (S1P1), sphingosphingosine-1-phosphat receptor 2 (S1P2), sphingosphingosine-1-phosphate receptor 3 (S1P3), sphingosphingosine-1-phosphate receptor 4 (S1P4), sphingosphingosine-1-phosphate receptor 5 (S1P5), sphingosphingosine-1-phosphate phosphatase 1 (SGPP1), sphingosphingosine-1-phosphate phosphatase 2 (SGPP2), ceramide synthase 1 (LASS1), ceramide synthase 2 (LASS2), ceramide synthase 3 (LASS3), ceramide synthase 4 (LASS4), ceramide synthase 5 (LASS5), ceramide synthase 6 (LASS6), acid ceramidase 1 (ASAH1), acid ceramidase 2 (ASAH2), alkaline ceramidase 1 (ACER1), alkaline ceramidase 2 (ACER2), alkaline ceramidase 3 (ACER3), ceramide kinase (CERK), ceramide kinase like (CERKL), sphingomyelin synthase 1 (SGMS1), sphingomyelin synthase 2 (SGMS2), acid sphingomyelinase 1 (SMPD1), neutral sphingosphingomyelinase 2 (SMPD2), neutral sphingomyelinase 3 (SMPD3), neutral sphingomyelinase 4 (SMPD4), and alkaline sphingomyelinase (ENPP7). No expression or almost no expression has been detected for ACER1, ASAH2, ENPP7, S1P1 S1P4 and S1P5 in retinoblastoma tissue, WERI Rb1, and WERI EtoR. For ASAH1, CERK, LASS1, LASS2, LASS6, S1P3, SGPP1, SGPP2, SMPD2, and SPHK1 the lowest expression was seen in retinoblastoma tissue and the highest in WERI EtoR. Taken together, the similar sphingolipid enzyme mRNAs, and especially SPHK1 and SPHK2, are all expressed in four human retinoblastoma samples and in WERI Rb1 and WERI EtoR. Differences have been found between native tissue and both cell lines in relative expression of these enzymes.
Discussion
The objective of this study was to test, whether etoposide alters the level of glucosyl-ceramide, ceramide, sphingosine, and sphingosine-1-P in parental retinoblastoma cells (WERI Rb1) or their etoposide-resistant subclone (WERI EtoR). Data from this study demonstrate significant upregulation of sphingosine expression following etoposide treatment in WERI Rb1 and WERI EtoR and therefore presume an apoptotic signal in both cell lines. Up-regulation of survival favoring sphingosine-1-P was only seen in therapy-resistant WERI EtoR following etoposide treatment, but not in chemotherapy-sensitive WERI Rb1. Therefore, we assume a survival signal in WERI EtoR, which might explain etoposide-resistance. In accordance with the sphingosine data, small decrease in glucosyl-ceramide and ceramide levels was detected following etoposide therapy, which might be a result of a consumptive shift to sphingosine in WERI Rb1 and WERI EtoR. As etoposide-induced downregulation of apoptotic ceramide and at the same time cell death in WERI Rb1, this suggests that there might be other apoptotic mechanisms leading to etoposide-vulnerable WERI Rb1, which is not in WERI EtoR. Taken together, these data may indicate a functional role of sphingosine-1-P in retinoblastoma chemotherapy resistance, but seems not to be the only resistance mechanism.
Experiments to demonstrate sphingolipid differences following treatment were conducted with previously described etoposide-sensitive WERI Rb1 and etoposide-resistant WERI EtoR [29] . Key analysis of our study, measurements of sphingosine, sphingosine-1-P, glucosyl-ceramide and ceramide, were performed by Q-TOF mass spectrometry, as described before [31] [32] [33] . Realizing the role of sphingolipid enzymes (especially SPHK1 and SPHK2) in sphingosine-1-P chemotherapy resistance of different tumor cells, we investigated their mRNA expression in four human retinoblastoma samples and in . Statistical analysis was done by Anova with Tukeys post-test. p values <0.05 are set as significant (*); p < 0.01 as **, p < 0.001 as *** WERI Rb1 and WERI EtoR in this study. We did not only see an upregulation of sphingosine-1-P in retinoblastoma chemotherapy-resistant cells, but also demonstrated similarity of sphingolipid metabolism in the used WERI Rb1 and WERI EtoR cell models as well in human retinoblastoma tissue.
Our results are consistent with findings from other study groups for sphingosine-1-P and SPHK1 and 2 in other diverse tumors. For example, SPHK1-siRNA-knockout experiments showed a reduction of sphingosine-1-P-levels and a reduced proliferation in prostatic tumor cells, pancreatic tumor cells, and leukemia cells [25] [26] [27] [28] 35] . Furthermore, sphingosine-1-P expression upregulation was seen after treatment in daunorubicin-resistant leukemia [28, 35] . Interestingly, increased SPHK1 expression has been also demonstrated in human samples of stomach tumors, lung tumors, kidney tumors, non-Hodgkin-lymphoma, colon carcinoma, astrocytoma, glioblastoma, and breast cancer [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] . In particular, in breast cancer, high SPHK1 expression is associated with unfavorable prognosis [20, 21] . Furthermore, in-vitro-SPHK1-overexpression leads to transformation of benign NIH3T3 fibroblasts into fibrosarcomas [36] . This phenomenon is reversible after competitive SPHK1 inhibition with N,N′-dimethylsphingosine [36] . Moreover, SPHK1 expression levels are correlated with chemotherapy resistance in prostatic tumor cells, pancreatic tumor cells, and leukemia cells [25] [26] [27] [28] . Also, increased doxorubicin-induced apoptosis rates are demonstrated in breast cancer, gliobastoma, and colon tumor SPHK2-siRNA-knockout-celllines [16, 37] .
Further experiments manipulating sphingolipid metabolism enzymes in chemotherapy-resistance retinoblastoma cells are planned in order to better understand the significance of sphingosine-1-P function in retinoblastoma chemotherapy resistance and chemotherapy vulnerability in these cells.
